Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Interest & Investment Income (2016 - 2026)

Integra Lifesciences Holdings' Interest & Investment Income history spans 17 years, with the latest figure at $4.4 million for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 10.85% to $4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 million, a 7.81% decrease, with the full-year FY2025 number at $18.5 million, down 7.81% from a year prior.
  • Interest & Investment Income hit $4.4 million in Q4 2025 for Integra Lifesciences Holdings, down from $5.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for IART hit a ceiling of $5.3 million in Q4 2022 and a floor of $1.4 million in Q1 2022.
  • Historically, Interest & Investment Income has averaged $3.7 million across 5 years, with a median of $4.4 million in 2025.
  • Biggest five-year swings in Interest & Investment Income: tumbled 33.78% in 2021 and later soared 269.08% in 2022.
  • Tracing IART's Interest & Investment Income over 5 years: stood at $1.4 million in 2021, then soared by 269.08% to $5.3 million in 2022, then dropped by 14.35% to $4.5 million in 2023, then increased by 7.56% to $4.9 million in 2024, then fell by 10.85% to $4.4 million in 2025.
  • Business Quant data shows Interest & Investment Income for IART at $4.4 million in Q4 2025, $5.0 million in Q3 2025, and $4.7 million in Q2 2025.